Patents for A61P 35 - Antineoplastic agents (221,099)
01/2010
01/14/2010US20100008902 P450rai-2 (p450 cytochrome 26b), encoding nucleic acid molecules and methods and uses thereof
01/14/2010US20100008901 Methods for the treatment and prevention of cancer
01/14/2010US20100008896 Use of Fenretinide or Bioactive Derivatives Thereof and Pharmaceutical Compositions Comprising the Same
01/14/2010US20100008888 Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas
01/14/2010US20100008855 Production and Use of Novel Peptide-Based Agents with Bispecific Antibodies
01/14/2010US20100008852 Bi-specific monoclonal antibody (specific for both cd3 and cd11b) therapeutic drug
01/14/2010DE10235602B4 Metallcluster-Nanoverbindungen zur Behandlung von Tumorerkrankungen Metal nano-cluster compounds for the treatment of tumor diseases
01/14/2010CA2756053A1 Alpha-galactosyl ceramide analogs and their use as immunotherapies, adjuvants, and antiviral, antibacterial, and anticancer agents
01/14/2010CA2743975A1 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
01/14/2010CA2734348A1 Glycopeptide constructs and uses thereof
01/14/2010CA2730591A1 9-alpha estratriene derivatives as er-beta selective ligands for the prevention and treatment of intestinal cancer
01/14/2010CA2730319A1 Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
01/14/2010CA2730314A1 Bicyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
01/14/2010CA2730311A1 Icotinib hydrochloride, synthesis, crystalline forms, drug combinations, and uses thereof
01/14/2010CA2730308A1 Peptides and their use as carriers into cancer cells
01/14/2010CA2730300A1 Fgf-r4 receptor-specific antagonists
01/14/2010CA2730271A1 Pi3k isoform selective inhibitors
01/14/2010CA2730270A1 Dicarba-analogues of octreotide
01/14/2010CA2730257A1 2-methylene-19,26-dinor-(20s,22e,25r)-vitamin d analogs
01/14/2010CA2730254A1 2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin d analogs
01/14/2010CA2730251A1 Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
01/14/2010CA2730248A1 2-methylene-(20e)-20(22)-dehydro-19-nor-vitamin d analogs
01/14/2010CA2730247A1 2-methylene-20(21)-dehydro-19-nor-vitamin d analogs
01/14/2010CA2730244A1 2-methylene-19,26-dinor-(20r,22e,25r)-vitamin d analogs
01/14/2010CA2730231A1 Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
01/14/2010CA2730201A1 Pharmaceutical composition for treatment and prevention of cancer
01/14/2010CA2730110A1 Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
01/14/2010CA2730106A1 Kinase inhibitors and methods of use
01/14/2010CA2730088A1 Immunity-inducing agent and method for detection of cancer
01/14/2010CA2730085A1 Functional micelles for hard tissue targeted delivery of chemicals
01/14/2010CA2730079A1 Processes for the preparation of crystalline forms of sunitinib malate
01/14/2010CA2730071A1 Antineoplastic derivatives of 4-oxo-l, 4-dihydro-quinolin?, preparation thereof, and therapeutic use thereof
01/14/2010CA2730010A1 Inhibitors of janus kinases
01/14/2010CA2729988A1 Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
01/14/2010CA2729943A1 Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
01/14/2010CA2729896A1 Substituted 1-benzyl-cinnolin-4(1h)-one derivatives, preparation thereof, and therapeutic use thereof
01/14/2010CA2729833A1 Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof
01/14/2010CA2729633A1 Tumor-initiating cells and methods of use
01/14/2010CA2729602A1 Notch1 receptor binding agents and methods of use thereof
01/14/2010CA2729351A1 Fn14/trail fusion proteins
01/14/2010CA2729306A1 Notch-binding agents and antagonists and methods of use thereof
01/14/2010CA2728347A1 Lm-1 antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
01/14/2010CA2728344A1 Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
01/14/2010CA2728343A1 18f-labelled three- and four-carbon acids for pet imaging
01/14/2010CA2727574A1 Multi-leu peptides and analogues thereof as selective pace4 inhibitors and effective antiproliferative agents
01/14/2010CA2727388A1 Anti-tumor immunotherapy
01/14/2010CA2727282A1 Novel pyrrolidine derivatives as metap-2 inhibitors
01/13/2010EP2144065A1 HLA-E Binding
01/13/2010EP2143795A2 Anti-CD20 monoclonal antibody
01/13/2010EP2143794A1 Viral vector for gene therapy
01/13/2010EP2143731A1 Compounds for immunotherapy of prostate cancer and methods for their use
01/13/2010EP2143444A1 Compositions for inhibition of anglogenesis
01/13/2010EP2143442A1 Treatment of solid tumors with tissue inhibitors of metalloproteinases(TIMPs)
01/13/2010EP2143441A1 Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
01/13/2010EP2143438A1 Compositions and methods for the diagnosis and treatment of tumor
01/13/2010EP2143437A1 Compositions and methods for the diagnosis and treatment of tumor
01/13/2010EP2143432A1 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
01/13/2010EP2143428A1 Tamibarotene capsule preparation
01/13/2010EP2143424A1 Oral pharmaceutical preparation for colon-specific delivery
01/13/2010EP2142669A2 Sirtuin based methods and compositions for treating b- catenin-related conditions
01/13/2010EP2142569A2 Non-fucosylated antibodies
01/13/2010EP2142568A1 Antibodies that bind both il-17a and il-17f and methods of using the same
01/13/2010EP2142567A2 The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases
01/13/2010EP2142544A1 Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
01/13/2010EP2142543A1 Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
01/13/2010EP2142535A2 3-imidazolyl-indoles for the treatment of proliferative diseases
01/13/2010EP2142531A1 Benzimidazole cannabinoid agonists
01/13/2010EP2142518A1 3,4-dihydroquinazoline derivatives
01/13/2010EP2142505A1 Sulfonamides and pharmaceutical compositions thereof
01/13/2010EP2141994A1 Multi-ring compounds and uses thereof
01/13/2010EP2035385B1 Inhibitors of akt (protein kinase b)
01/13/2010EP1660095B1 Tricyclic parp inhibitors
01/13/2010EP1499886B1 Methods and compositions for inducing an immune response
01/13/2010EP1465886B1 Bipyridinyl derivatives as a highly selective cyclooxygenase-2 inhibitor
01/13/2010EP1406910B1 Preparation methods of derivatives of bisphosphonates
01/13/2010EP1394253B1 Anti-human ovarian cancer -anti-cd3 bispecific antibody
01/13/2010EP1360500B1 Methods for selective targeting
01/13/2010EP1305322B1 Derivatives of branched-chain lipophilic molecules and uses thereof
01/13/2010EP1255725B1 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents
01/13/2010EP1144388B1 Acyl derivatives which treat vla-4 related disorders
01/13/2010CN100580085C Adenovirus/alpha virus hybrid vector for the effective administration and expression of therapeutic genes in tumour cells
01/13/2010CN100580080C Corona-virus-like particles comprising functionally deleted genomes
01/13/2010CN100579989C Interfusion protein between diphtheria toxin and GM-CSF mutant, coded gene and application
01/13/2010CN100579988C Interfusion protein between diphtheria toxin and GM-CSF mutant, coded gene and application
01/13/2010CN100579980C Ru(II) complex with anticancer liveness and method for preparing the same
01/13/2010CN100579582C Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the preparation of medicament for treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of aller
01/13/2010CN100579577C Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
01/13/2010CN100579536C Preparation method for graininess medicine containing hirsutella hepia - cordyceps fungus powder
01/13/2010CN100579535C Improvements in or relating to immune functions
01/13/2010CN100579527C Compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes and use method thereof
01/13/2010CN100579523C Dihydroartemisinin emulsion for injection, freeze-dried emulsion and preparation method thereof
01/13/2010CN100579512C Method of producing water-solubility hypocrellin titanium dioxide nano granule
01/12/2010US7645788 Treating breast cancer cells which are both estrogen-dependent and estrogen-negative; chemical systhesis by reacting indole-3-carbinol with an oxidizing agent in a solvent, cyclization, purification
01/12/2010US7645782 Ethyl (2Z,5S,6E)-5-(tert-Butyl-dimethyl-silanyloxy)-2,6-dimethyl-7-(2-methyl-1,3-thiazol-4-yl)-hepta-2,6-dienoate; (3S)-3-(tert-Butyl-dimethyl-silanyloxy)-tetrahydrofuranone; breast , epidermoid, ovarian, lung, prostate cancer, cervix carcinoma, cancer of the bladder or leukemia
01/12/2010US7645779 Linked biaryl compounds
01/12/2010US7645774 Sulfonamide-containing benzene derivatives; cancer and inflammatory, immunomodulatory or respiratory diseases; allergy, seasonal allergic rhinitis, reversible airway obstruction, adult respiratory distress syndrome, asthma, or bronchitis
01/12/2010US7645768 Production of polyketides and other natural products
01/12/2010US7645764 Kinase inhibitors and methods for using the same
01/12/2010US7645762 Substituted pyrazolo[1,5-a] pyrimidines as protein kinase inhibitors
01/12/2010US7645761 Indoline derivatives